Reusing Reclaimed Precast Concrete Elements in New Buildings – Tampere University, Finland, Coordinates a Major International Project
25.5.2021 08:00:00 EEST | Business Wire | Press release
Concrete is widely used as a construction material, but it has a substantial environmental impact. When a building is demolished, what happens to all the concrete? Tampere University, Finland, is coordinating the new international ReCreate project, which aims to discover how used concrete elements can be deconstructed without damaging them and reused in new buildings – and to turn the process into a profitable business. The four-year project has received €12.5 million of funding under the EU’s Horizon 2020 programme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005850/en/
When a building is demolished, what happens to all the concrete? Tampere University, Finland, is coordinating the new international ReCreate project, which aims to discover how used concrete elements can be deconstructed without damaging them and reused in new buildings – and to turn the process into a profitable business. Photo by Tampere University.
Concrete has been the world’s most commonly used building material for at least half a century. It accounts for the majority of both construction materials and demolition waste. In Europe, concrete buildings are commonly constructed using precast concrete elements. If the old elements could be reused instead of manufacturing new ones, it would bring major benefits for the environment.
“By reusing concrete elements, we can save an enormous amount of energy and raw materials,” says Satu Huuhka, adjunct professor at the Faculty of Built Environment at Tampere University, who leads the ReCreate project.
The recently launched international ReCreate project (2021–2025) coordinated by Tampere University seeks to find new uses for the concrete elements of condemned buildings in the construction of new buildings. The four-year project has received funding under the European Union’s Horizon 2020 call, and it seeks solutions for reusing construction and demolition waste. The project has an overall budget of €12.5 million. The project involves universities and regional company clusters in four countries: Finland, Sweden, the Netherlands, and Germany. The communications partner is the Croatia Green Building Council. All the country clusters will carry out their own pilot projects where they deconstruct precast concrete elements intact and reuse them in a new building.
“We are specifically looking to reuse the concrete elements as a whole, not as a raw material for something new,” Huuhka points out.
Tapping into Finland’s world-class expertise
Researchers at the Faculty of Built Environment have been carrying out ground-breaking research into the circular economy in the construction sector for a decade. In addition, long-term research on renovation and the lifecycle engineering of structures provides a solid foundation for the development of quality assurance procedures that will ensure the safety and integrity of the reused elements. This time, the researchers are set to explore not only the technical implementation of the solutions but also the business perspective.
“There are many questions to be answered. How do we deconstruct the elements from buildings without damaging them? How do we assess their structural integrity? How do we recertify the salvaged elements and turn them into a product that meets building code requirements? Since the elements are not of uniform quality, how can we turn this into a viable business? We must also consider the social aspects: does the process require new skills or new ways of working?” Huuhka asks.
Tampere University researchers will also bring to the project their specialist expertise in circular economy business models, building regulations and law, and occupational sociology. The Finnish country cluster comprises Tampere University, the construction company Skanska, the demolition company Umacon, the precast concrete company Consolis Parma, the engineering and consultancy company Ramboll, the architecture firm Liike Oy Arkkitehtistudio and the City of Tampere.
Tampere University
The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005850/en/
Contact information
Inquiries:
Adjunct Professor Satu Huuhka
Faculty of Built Environment, Tampere University
tel. +358 50 3009 263
satu.huuhka@tuni.fi
Project manager Tommi Halonen
Sustainable Tampere 2030 programme, City of Tampere
tel. +358 44 481 1007
tommi.halonen@tampere.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
